title: In reply to 'False-positive Xpert® MTB/RIF assays in previously treated patients'.
authors: Cochrane Infectious Diseases Group, Liverpool School of Tropical Medicine, Liverpool, UK.
authors: Karen R
authors: KR
authors: Steingart
authors: Department of Clinical Epidemiology, McGill University Health Centre, Montreal, QC, Canada.
authors: Ian
authors: I
authors: Schiller
authors: Department of Clinical Epidemiology, McGill University Health Centre, Montreal, QC, Canada.
authors: Nandini
authors: N
authors: Dendukuri
mesh_terms: D000904:Antibiotics, Antitubercular / Q000627:therapeutic use*; D024881:Drug Resistance, Bacterial; D005260:Female; D006801:Humans; D009169:Mycobacterium tuberculosis / Q000187:drug effects* / Q000302:isolation & purification*; D021141:Nucleic Acid Amplification Techniques / Q000379:methods*; D012141:Respiratory Tract Infections / Q000175:diagnosis*; D012293:Rifampin / Q000627:therapeutic use*; D014376:Tuberculosis / Q000175:diagnosis*; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy*
chemical_list: D000904:Antibiotics, Antitubercular; D012293:Rifampin